A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study of vapendavir treatment of
laboratory-confirmed and symptomatic HRV infection of the upper respiratory tract in
allogeneic and autologous stem cell transplant subjects. The aim of this study is to evaluate
the effect of vapendavir on laboratory-confirmed HRV upper-respiratory tract infection in
HSCT patients, as measured by viral load changes, worsening of upper respiratory tract
infection (URTI) to lower respiratory tract infection (LRTI), duration of clinical symptoms,
the occurrence of supplemental oxygen use, duration of viral shedding, hospital admission and
duration of hospitalization, incidence of secondary bacterial infection, and mortality rates.
Additionally, the safety and tolerability of vapendavir, and the vapendavir plasma levels
achieved in the HSCT population, and the profile of viral resistance development will also be
assessed.